GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Price-to-Funds-From-Operations

Ensol Biosciences (XKRX:140610) Price-to-Funds-From-Operations : (As of Jan. 18, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Ensol Biosciences Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.